

Rahul Chaudhary, Facp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3964359/publications.pdf>

Version: 2024-02-01

69
papers

1,247
citations

516561

16
h-index

414303

32
g-index

70
all docs

70
docs citations

70
times ranked

2261
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Internal Jugular Venous Ultrasound in suspected or confirmed Heart Failure: A Systematic Review. <i>Journal of Cardiac Failure</i> , 2022, 28, 639-649.	0.7	6
2	Heart Failure Trial Update—Analysis of Recent Data. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 2792-2800.	0.6	5
3	Effect of serum zinc and copper levels on insulin secretion, insulin resistance and pancreatic β^2 cell dysfunction in US adults: Findings from the National Health and Nutrition Examination Survey (NHANES) 2011–2012. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108627.	1.1	13
4	Carotid access for transcatheter aortic valve replacement: A meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 723-733.	0.7	7
5	Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 454-465.	1.0	14
6	Improving Outcomes in Cardiovascular Diseases. <i>Cardiology in Review</i> , 2021, Publish Ahead of Print, .	0.6	4
7	Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 902-904.	1.0	13
8	Naltrexone Initiation in the Inpatient Setting for Alcohol Use Disorder: A Systematic Review of Clinical Outcomes. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 495-501.	1.2	9
9	Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 388-402.	1.2	51
10	BRASH: Case Report and Review of Literature. <i>Hearts</i> , 2021, 2, 302-306.	0.4	5
11	Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-Wide Sample of Hospitalized COVID-19–Positive Compared With COVID-19–Negative Patients. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1718-1726.	1.4	11
12	Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19. <i>Thrombosis Research</i> , 2021, 207, 150-157.	0.8	24
13	Deep Vein Thrombosis after COVID-19 Vaccinations. <i>Blood</i> , 2021, 138, 291-291.	0.6	4
14	Direct oral anticoagulants: a review on the current role and scope of reversal agents. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 271-286.	1.0	52
15	Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2020, 120, 565-586.	0.4	106
16	Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 23-35.	1.9	13
17	Investigational drugs in phase II clinical trials for acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 33-47.	1.9	8
18	First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition. <i>Circulation</i> , 2020, 142, 1305-1307.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1594-1596.	1.8	33
20	Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. <i>EClinicalMedicine</i> , 2020, 29-30, 100647.	3.2	17
21	Vorapaxar in the treatment of cardiovascular diseases. <i>Future Cardiology</i> , 2020, 16, 373-384.	0.5	10
22	Rivaroxaban-induced hemorrhagic pericardial tamponade in end-stage renal disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 982-983.	1.0	1
23	Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a caseâ€“control study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 484-498.	1.0	10
24	Venous Thromboembolism Prophylaxis: Need for Continuous Assessment Due to Changes in Risk During the Same Hospitalization. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 170-175.	1.2	2
25	DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Metaâ€“Analysis. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2021-2026.	1.3	7
26	Abstract 16676: Heightened Platelet Function: An Unrecognized Component of the Covid Hypercoagulability State. <i>Circulation</i> , 2020, 142, .	1.6	1
27	Role of gut microbiota in cardiovascular diseases. <i>World Journal of Cardiology</i> , 2020, 12, 110-122.	0.5	96
28	Six Sigma approach to reduce door-to-balloon time for patients with STEMI. <i>American Journal of Managed Care</i> , 2020, 26, e140-e141.	0.8	0
29	Demystifying airline syncope. <i>World Journal of Cardiology</i> , 2020, 12, 107-109.	0.5	1
30	Telemetry: appropriateness of initial assignment and duration in nonintensive setting. <i>American Journal of Managed Care</i> , 2020, 26, 459-460.	0.8	2
31	â€œBlueprintingâ€•thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 192-199.	1.0	14
32	Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 373-381.	1.0	14
33	Percutaneous Coronary Intervention in Older Patients With ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1890-1900.	1.2	45
34	Predictors of 30-day readmissions after catheter ablation for atrial fibrillation in the USA. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 55, 243-250.	0.6	10
35	HDL3-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 1001-1006.	0.3	6
36	Role of Prophylactic Magnesium Supplementation in Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting: a Systematic Review and Meta-Analysis of 20 Randomized Controlled Trials.. <i>Journal of Atrial Fibrillation</i> , 2019, 12, 2154.	0.5	17

#	ARTICLE	IF	CITATIONS
37	In search for an optimal antithrombotic regimen in patients with atrial fibrillation undergoing stenting. <i>Kardiologia Polska</i> , 2019, 77, 817-819.	0.3	0
38	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 653-665.	0.9	15
39	His Bundle Pacing. <i>Cardiology in Review</i> , 2018, 26, 201-206.	0.6	10
40	Thirty-day readmissions after cardiac implantable electronic devices in the United States: Insights from the Nationwide Readmissions Database. <i>Heart Rhythm</i> , 2018, 15, 708-715.	0.3	11
41	Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. <i>Atherosclerosis</i> , 2018, 268, 55-62.	0.4	5
42	Cangrelor for the treatment of patients with Arterial Thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1389-1398.	0.9	5
43	Coronary Artery Disease in Patients With Disorders of Bilirubin Excretion. <i>American Journal of Therapeutics</i> , 2017, 24, e653-e658.	0.5	0
44	On-X Valve. <i>Cardiology in Review</i> , 2017, 25, 77-83.	0.6	22
45	Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 437-445.	1.0	63
46	Right ventricular apical versus non-apical implantable cardioverter defibrillator lead: A systematic review and meta-analysis. <i>Journal of Electrocardiology</i> , 2017, 50, 591-597.	0.4	5
47	Reply. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 105-106.	1.1	0
48	Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 123-131.	0.9	6
49	Low-density lipoprotein 4: a novel predictor of coronary artery disease severity. <i>Current Medical Research and Opinion</i> , 2017, 33, 1979-1984.	0.9	11
50	Central aortic pulse pressure, thrombogenicity and cardiovascular risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 223-233.	1.0	8
51	Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 49, 263-270.	0.6	10
52	Venous Thromboembolism Prophylaxis: Inadequate and Overprophylaxis When Comparing Perceived Versus Calculated Risk. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2017, 1, 242-247.	1.2	5
53	PCSK9 inhibitors: A new era of lipid lowering therapy. <i>World Journal of Cardiology</i> , 2017, 9, 76.	0.5	200
54	Erythropoietin therapy after out-of-hospital cardiac arrest: A systematic review and meta-analysis. <i>World Journal of Cardiology</i> , 2017, 9, 830-837.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials. <i>International Journal of Cardiology</i> , 2016, 218, 235-239.	0.8	5
56	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1365-1370.	1.2	10
57	Therapeutic Hypothermia and Stent-Associated Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1801-1811.	1.1	34
58	Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2016, 118, 1941-1947.	0.7	17
59	Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2016, 113, 40-45.	1.0	16
60	Oxidized Low-Density Lipoprotein- β 2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2016, 118, 673-678.	0.7	9
61	Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography. <i>Journal of Interventional Cardiology</i> , 2016, 29, 168-178.	0.5	13
62	Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 779-791.	0.6	3
63	Association of weight gain with coronary artery disease, inflammation and thrombogenicity. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 394-403.	1.0	5
64	Ivabradine. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 335-343.	1.0	20
65	Safety and efficacy of uninterrupted periprocedural rivaroxaban in patients undergoing atrial fibrillation catheter ablation: A metaanalysis of 1,362 patients. <i>International Journal of Cardiology</i> , 2016, 203, 906-908.	0.8	6
66	Cryoballoon versus Radiofrequency Ablation for Atrial Fibrillation: A Meta-analysis of 16 Clinical Trials. <i>Journal of Atrial Fibrillation</i> , 2016, 9, 1429.	0.5	11
67	Bilirubin in coronary artery disease: Cytotoxic or protective?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 469.	0.6	22
68	Safety And Efficacy Of Uninterrupted Periprocedural Apixaban In Patients Undergoing Atrial Fibrillation Catheter Ablation: A Metaanalysis Of 1,057 Patients. <i>Journal of Atrial Fibrillation</i> , 2016, 8, 1368.	0.5	8
69	Surgical Sepsis and Organ Crosstalk: The Role of the Kidney. <i>Journal of Surgical Research</i> , 2011, 167, 306-315.	0.8	49